160 related articles for article (PubMed ID: 17117724)
1. The role of PET scanning in determining pharmacoselective doses in oncology drug development.
Price P
Ernst Schering Res Found Workshop; 2007; (59):185-93. PubMed ID: 17117724
[TBL] [Abstract][Full Text] [Related]
2. Radiopharmaceuticals for oncology drug development: a pharmaceutical industry perspective.
Murphy PS; Bergström M
Curr Pharm Des; 2009; 15(9):957-65. PubMed ID: 19275660
[TBL] [Abstract][Full Text] [Related]
3. Clinical molecular imaging with positron emission tomography.
Saleem A; Charnley N; Price P
Eur J Cancer; 2006 Aug; 42(12):1720-7. PubMed ID: 16797972
[TBL] [Abstract][Full Text] [Related]
4. The role of positron emission tomography in the discovery and development of new drugs; as studied in laboratory animals.
Roselt P; Meikle S; Kassiou M
Eur J Drug Metab Pharmacokinet; 2004; 29(1):1-6. PubMed ID: 15151164
[TBL] [Abstract][Full Text] [Related]
5. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography imaging as a key enabling technology in drug development.
McCarthy TJ
Ernst Schering Res Found Workshop; 2007; (62):329-39. PubMed ID: 17172162
[TBL] [Abstract][Full Text] [Related]
7. Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine.
Wells P; West C; Jones T; Harris A; Price P
Biochim Biophys Acta; 2004 Dec; 1705(2):91-102. PubMed ID: 15588764
[TBL] [Abstract][Full Text] [Related]
8. Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET.
Brady F; Luthra SK; Brown GD; Osman S; Aboagye E; Saleem A; Price PM
Curr Pharm Des; 2001 Dec; 7(18):1863-92. PubMed ID: 11772355
[TBL] [Abstract][Full Text] [Related]
9. Positron emitting tracers in pre-clinical drug development.
Fernandes E; Barbosa Z; Clemente G; Alves F; Abrunhosa AJ
Curr Radiopharm; 2012 Apr; 5(2):90-8. PubMed ID: 22280107
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography and neoadjuvant therapy of breast cancer.
Cochet A; Generali D; Fox SB; Ferrozzi F; Hicks RJ
J Natl Cancer Inst Monogr; 2011; 2011(43):111-5. PubMed ID: 22043055
[TBL] [Abstract][Full Text] [Related]
11. Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: fluorodeoxyglucose and nonfluorodeoxyglucose tracers.
Wong KK; Arabi M; Zerizer I; Al-Nahhas A; Rubello D; Gross MD
Nucl Med Commun; 2011 Sep; 32(9):764-81. PubMed ID: 21799367
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography molecular imaging for drug development.
Matthews PM; Rabiner EA; Passchier J; Gunn RN
Br J Clin Pharmacol; 2012 Feb; 73(2):175-86. PubMed ID: 21838787
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography as an imaging biomarker.
Weber WA
J Clin Oncol; 2006 Jul; 24(20):3282-92. PubMed ID: 16829652
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.
Bergström M; Grahnén A; Långström B
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):357-66. PubMed ID: 12937873
[TBL] [Abstract][Full Text] [Related]
15. Imaging of Tumor Metabolism Using Positron Emission Tomography (PET).
Apostolova I; Wedel F; Brenner W
Recent Results Cancer Res; 2016; 207():177-205. PubMed ID: 27557539
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
17. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
18. Positron Emission Tomography Computed Tomography: A Guide for the General Radiologist.
Beadsmoore C; Newman D; MacIver D; Pawaroo D
Can Assoc Radiol J; 2015 Nov; 66(4):332-47. PubMed ID: 26277234
[TBL] [Abstract][Full Text] [Related]
19. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.
O'Neill AF; Qin L; Wen PY; de Groot JF; Van den Abbeele AD; Yap JT
J Neurooncol; 2016 Dec; 130(3):495-503. PubMed ID: 27576699
[TBL] [Abstract][Full Text] [Related]
20. [The contribution of PET to radiation treatment planning].
Belkacémi Y; Lartigau E; Kerrou K; Carpentier P; Taïeb S; Giraud P
Bull Cancer; 2007 Jan; 94(1):99-108. PubMed ID: 17237010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
